Prostate cancer is now the most common cancer in the USA. It is estimated that 15.4% of men will be diagnosed with the cancer at some point in their lives and this incidence has risen dramatically over the past decade. The American Cancer Society predicts that in 1999, 179 300 men will be diagnosed with prostate cancer, and that an additional 37 000 men will die of the disease. However, the mortality rate peaked in 1991 at 26.5 out of 100 000 men and has declined to 17.5 out of 100 000 men in 1997. Figure 1 shows the mortality rate per 100 000 men for the following ®ve diseases (prostate cancer, ovarian cancer, lung cancer, breast cancer and HIV). These data suggest that with the exception of lung cancer, which affects both men and women, the mortality rate for prostate and breast cancer are higher than any other malignancy.
We suspected that in recent years, the number of prostate-focused articles has risen, but we were unsure how that would compare to other diseases. To assess this hypothesis we conducted MEDLINE searches for the ®ve diseases (prostate cancer, breast cancer, ovarian cancer, lung cancer and HIV). In 1997 there were 2386 publications referring to prostate cancer ( Figure 2 shows the number of publications for each disease since 1966). In the same year there were 7700, 5897, 3957 and 3121 publications on HIV, breast cancer, lung cancer and ovarian cancer, respectively. However, between 1990 and 1997 the number of publications on prostate cancer has doubled. During that same time period the number of publications for the other diseases only rose by 44% for breast cancer, 16% for ovarian cancer, 10% for lung cancer and 40% for HIV. Surprisingly, ovarian cancer had the highest number of publications per death, 0.41, and 14 500 deaths in 1995. Lung cancer Ð a disease which killed 157 400 in 1995 Ð although the leading cause of cancer related deaths had a diminutive 0.045 publications per death. HIV (which killed 32 505 in 1995) and breast cancer (which killed 46 000 in 1995) were higher than prostate cancer (0.171 and 0.205 publication/death, respectively). Prostate cancer (0.137 articles per death) although killing three times as many people as ovarian cancer, had about one third of the number of articles published per death, as ovarian cancer did.
Within the prostate cancer MEDLINE search we also searched eight additional terms (treatment, diagnosis, staging, surgery, radiation, animals, humans, genetics). Since 1996 the percentage of publications focused on the treatment of prostate cancer has remained relatively¯at (in 1966 40.4% of the total publications vs 50.5% in 1997). Those focused on diagnosis increased slightly during that period time (42.4% in 1967 vs 56.8% in 1997). However, the percentage of publications addressing staging of prostate cancer has increased dramatically (0.84% in 1973 compared with 15.13% in 1997). Not surprisingly those addressing the genetics of prostate cancer have also increased substantially (0.33% in 1969 vs 15.21% in 1997) . This correlates with improved molecular technology during that time. Surprisingly those publication addressing surgical management of prostate cancer have remained relatively constant (17.8% in 1966 vs 15.3% in 1997) . Radiation therapy for prostate cancer and animal studies focused on prostate models have both increased during that time period (0.59% in 1966 vs 9.2% in 1997; and 0.59% in 1966 vs 3.44% in 1997, respectively) .
In 1996 the number of HIV related articles published was more than three times the number of prostate cancer articles (7640 articles and 2144 articles, respectively). However, the mortality rate of HIV was only 0.83 times the mortality rate of prostate cancer (17.2 out of 100 000 and 20.8 out of 100 000, respectively). The discrepancy between the relation of HIV and prostate cancer articles and mortality may re¯ect the gap in funding between the two diseases. Additionally, while the mortality rates of breast cancer and prostate cancer remain relatively close, the gap between the number of articles published per disease is far greater than the gap in mortality. There are nearly 2.5 times as many breast cancer articles published, as there are prostate cancer articles.
The rise over the past eight years of publications addressing cancer is most likely a surrogate marker for an increase in research fund. Likewise the disparity in the number of publications for prostate cancer compared with other diseases may also re¯ect a discrepancy in the research funding. As a side note, scientists must now read 6.5 prostate cancer papers/8 h d/7 d per week in order to stay fully abreast of one malignancy. In addition, at the current rate of increase for peer reviewed publications within the medical literature, there will be one publication per prostate cancer death in 2010. Are we making an impact on prostate cancer? WD Figg and JR Blumenfeld
